Front & Back Matter

13 Pages·2014·1.92 MB·English

Oncology 88 | 1 | 15 print online www.karger.com/ocl
88(1) 1–68 (2015) ISSN 0030–2414 e-ISSN 1423–0232
International Journal of
Cancer Research and Treatment
S. Karger
Medical and Scientific Publishers
Basel . Freiburg . Paris .
London . New York . Chennai .
New Delhi . Bangkok . Beijing .
Shanghai . Tokyo . Kuala Lumpur .
Singapore . Sydney
A concise, compact, and handy manual:
Reduced revised and extended
list price
Pearls and Pitfalls in
Pearls and Pitfalls
in Head and Head and Neck Surgery
Neck Surgery
Practical Tips Practical Tips to
to Minimize Complications
2nd, revised and extended edition Minimize Complications
Editor
Claudio R. Cernea
Associate Editors
Fernando L. Dias
Dan Fliss Editor
Roberto A. Lima
Eugene N. Myers Claudio R. Cernea
William I. Wei
Associate Editors
Fernando L. Dias, Dan Fliss, Roberto A. Lima
Eugene N. Myers, William I. Wei
Pearls and Pitfalls in Head and Neck Surgery In this unique volume, leading international experts Contents
Practical Tips to Minimize Complications share their experiences in the management of head
Editor: Cernea, C.R. (São Paulo)
Associate Editors: Dias, F.L. (Rio de Janeiro); Fliss, and neck tumors, providing a guidebook for all sur- • Thyroid and Parathyroid Glands
D. (Tel Aviv); Lima, R.A. (Rio de Janeiro); Myers, geons dealing with head and neck neoplasms. • Neck Metastases
E.N. (Pittsburgh, Pa.); Wei, W.I. (Hong Kong) Each chapter offers a concise description of useful • Oral/Oropharyngeal Tumors
212 p., hard cover, 2012
CHF 49.00 / EUR 41.00 / USD 79.00 ‘pearls’ and dangerous ‘pitfalls’ which must be avoid- • Laryngeal Tumors
Prices subject to change ed. Contributions cover topics from thyroid glands, • Hypopharyngeal Cancer
EUR price for Germany, USD price for USA only neck metastases, and oral tumors to laryngeal, pha- • Nasopharyngeal Cancer
ISBN 978–3–8055–9972–6
e-ISBN 978–3–8055–9973–3 ryngeal, and nasopharyngeal tumors, as well as sali- • Salivary Gland Tumors
vary gland tumors, skull base tumors, and reconstruc- • Skull Base Tumors
tion surgery. In addition to frequent diseases which • Vascular Tumors
Fields of interest: Otorhinolaryngology; Neurosurgery;
Oncology; Endocrinology, Maxillofacial Surgery, are encountered in everyday practice, some new • Parapharyngeal Space Tumors
Oral Surgery, Surgery therapeutic topics such as video-assisted thyroidec- • Infections of Head and Neck
tomy, robotic surgery, and management of the neck • Tracheostomy
after organ preservation treatment are discussed. • Reconstruction
The 2nd edition has been extended by topical chap- • Miscellaneou
ters of major practical interest including the latest
findings and techniques. The new chapters are clear-
ly indicated and can be recognized easily.
Head and neck surgeons, otolaryngologists, neuro-
surgeons, maxillofacial surgeons, plastic surgeons,
radiation and clinical oncologists, and general sur-
geons, as well as students and residents interested in
the management of head and neck tumors, will find
this publication an indispensable manual.
Dear Librarian
I have reviewed this publication and
would like to recommend it for our library.
Recommended by:
Department:
Date:
The easiest way to order: www.karger.com/PPHNS2
Signature:
Karger – Medical and Scientific Publishers
CH–4009 Basel, Switzerland
Orders may be placed with any bookshop,
[email protected], f: [phone]
subscription agency, directly with the publisher
www.karger.com
or through a Karger distributor.
KI15201
GzD 2015
EB 8.12.14
GL 8.12.14
GI 8.12.14
International Journal of Cancer Research and Treatment
Founded 1948 as ‘Oncologia’ by H.R. Schinz
Continued by V. Richards (1967–1975), H. Wrba (1976–1992), P.P. Carbone (1993–2002),
D.L. Trump (2002–2007)
Editor-in-Chief Editorial Board
M. Markman, Philadelphia, Pa. A.B. Benson, Chicago, Ill.
A. Chang, Singapore
A.L. Cheng, Taipei
Associate Editor J.F. Cleary, Madison, Wis.
M. Dietel, Berlin
P. Dufour, Strasbourg M.S. Ernstoff, Cleveland, Ohio
M.G. Fakih, Duarte, Calif.
J.J. Grau, Barcelona
H. Gronemeyer, Illkirch
Regional Editor Japan
D.F. Hayes, Ann Arbor, Mich.
C.S. Johnson, Buffalo, N.Y.
O. Hino, Tokyo
M.J. Kelley, Durham, N.C.
L. Kumar, New Delhi
P.J. Loehrer, Indianapolis, Ind.
J.R. Marshall, Buffalo, N.Y.
S. Monfardini, Milan
R. Nagler, Haifa
R. Ohno, Nagoya
B. Pestalozzi, Zurich
H.M. Pinedo, Amsterdam
E.A. Repasky, Buffalo, N.Y.
A. Semczuk, Lublin
E.F. Smit, Amsterdam
C.N. Sternberg, Rome
R. Stupp, Zurich
M.S. Tallman, Chicago, Ill.
S. Tanaka, Hiroshima
M. Tian, Houston, Tex.
D.L. Trump, Buffalo, N.Y.
T. Wiegel, Ulm
W. Yasui, Hiroshima
H. Zhang, Hangzhou City
Printed in Germany on acid-free and non-aging paper
(ISO 9706) by Stückle Druck, Ettenheim
Guidelines for Authors
Submission in its revised version of 1975 and its amendments of on general scientific or medical subjects in oncology
Original papers and reviews written in English are 1983, 1989, and 1996 [JAMA 1997;277:925–926]. Ac- are also welcome. The length should not exceed 500
considered for publication. Manuscripts should cordingly, the subject’s informed consent has to be words.
be submitted to Oncology online and must be ac- mentioned in the manuscript. Information suitable to
companied by a cover letter signed by the submit- reveal the subject’s identity is to be avoided. Arrangement
ting/corresponding author on behalf of all co-au- Title page: The first page of each paper should indi-
thors. Assurance should be given that the man- Categories of Manuscripts cate the title, the authors’ names, the institute where
uscript is not under simultaneous consideration Reviews are comprehensive, state-of-the-art analyses the work was conducted, and a short title for use as
by any other publication. For specific instructions and investigations of important clinical problems. running head.
on how to prepare a manuscript for submission, Reviews must include a critical discussion of the re-
Full address: The exact postal address of the corre-
you are encouraged to view the guidelines at www. ported data and give a clear conclusion with the po-
sponding author complete with postal code must be
karger.com/ocl, where you will also find a link to the tential impacts on the standard of care. Reviews may
given at the bottom of the title page. Please also sup-
Submission Website. Names, postal and e-mail ad- be invited by the Editor, or they may be unsolicited
ply phone and fax numbers, as well as e-mail address.
dresses of at least four experts in the appropriate area submissions. Reviews are not subject to page charges.
of research must accompany each manuscript. Select- The maximum length of manuscripts in this category Key words: Please supply 3–10 key words in English
ed scientists will be invited to act as referees. Referees will be 5,000 words for text and tables (a table = 250 that reflect the content of the paper.
suggested should not be from the same institution as words per page), with a maximum of 5 tables and 50
Abstract: Papers submitted to the sections Reviews,
the author and should have expert knowledge of the references.
Clinical Studies, Clinical Translational Research Ar-
subject. Should you have any problems with your sub-
Clinical Studies and Clinical Translational Research ticles, Clinical Trial Notes and Reducing the World-
mission, please contact:
Articles are full-length research papers which will be wide Burden of Cancer need an abstract of up to 200
Dr. M. Markman considered for the journal. These articles cover top- words. Abstracts are recommended, but optional,
S. Karger AG ics relevant to clinical and translational studies in all for Short Communications and Editorials. Abstracts
Editorial Office ‘Oncology’ oncological fields. Note that manuscripts present- of papers submitted for publication that have clini-
CH–4009 Basel (Switzerland) ing laboratory-based research efforts must address a cal implications using human materials should be
Tel. [phone] clinically relevant issue (Translational Research). structured with subheadings as follows: Objective(s),
Fax [phone] Methods, Results, Conclusion(s).
Short Communications will focus on descriptions of
E-Mail [email protected]
important toxicities of novel therapies and highly Footnotes: Avoid footnotes. When essential, they are
Mailing address for courier deliveries only: unique oncology-related medical management is- numbered consecutively and typed at the foot of the
Allschwilerstr. 10 sues. The maximum length of manuscripts in this appropriate page.
CH–4055 Basel (Switzerland) category will be 1,000 words.
Tables and illustrations: Tables and illustrations (both
Clinical Trial Notes are designed for brief discussions numbered in Arabic numerals) should be prepared
Conditions
of clinical trials, with a particular focus on phase 1, on separate pages. Tables require a heading and fig-
All manuscripts are subject to editorial review. Manu-
phase 1/2, and phase 2 studies. Priority in this sec- ures a legend, also prepared on a separate page. Due to
scripts are received with the explicit understanding
tion will not be for studies with a ‘positive result’, but technical reasons, figures with a screen background
that they are not under simultaneous consideration
rather for well-conceived and conducted clinical re- should not be submitted. When p ossible, group sev-
by any other publication. The editors reserve the
search efforts. The maximum length of manuscripts eral illustrations in one block for reproduction (max.
right to improve style and, if necessary, return the submitted in this category will be 1,500 words, with a size 180  223 mm) or provide crop marks. Each il-
manuscript for rewriting to the author. Submission
maximum of 2 tables and 1 figure. The paper should lustration must be labelled with its number and the
of an article for publication implies the transfer of
be divided into four sections: Introduction, Methods, first author’s name. B/w half-tone and color illustra-
the copyright from the author to the publisher upon
Results, Discussion. Note that all manuscripts sub- tions must have a final resolution of 300 dpi after scal-
acceptance. Accepted papers become the permanent
mitted in this category will undergo rapid review for ing, line drawings one of 800–1,200 dpi. Figure files
property of Oncology and may not be reproduced by
acceptance or rejection. must not be embedded in a document file but sub-
any means, in whole or in part, without the written
mitted separately (see detailed instructions on the
consent of the publisher. It is the author’s responsibil- Reducing the Worldwide Burden of Cancer are country
Submission Website at www.karger.com/ocl).
ity to obtain permission to reproduce illustrations, reports describing a variety of regional, national or
tables, etc. from other publications. international efforts that focus on the unique aspects Color illustrations
All manuscripts originating from non-English speak- of the epidemiology of cancer, and the delivery of ed- Online edition: Color illustrations are reproduced
ing countries must be revised by a professional lin- ucational messages, preventive services, and oncolo- free of charge. In the print version, the illustrations
guistic reviewer and it must be evident from the cov- gy-related care within the developing world. Papers are reproduced in black and white. Please avoid re-
ering letter that this has been done. submitted for this section benefit from a higher quota ferring to the colors in the text and figure legends.
The editor reserves the right to reject papers based on of free pages. There are no page charges for papers of Print edition: Up to 6 color illustrations per page can
priorities and space availability in the journal. 8 or fewer printed pages. Each additional complete or be integrated within the text at CHF 800.00 per page.
partial page is charged to the author at CHF 325.00.
Conflicts of Interest References
Editorials are commentaries on current topics or on
Authors are required to disclose any sponsorship or In the text identify references by Arabic numerals [in
papers published elsewhere in the issue. Word count
funding arrangements relating to their research and square brackets]. Material submitted for publication
limit is 1,500 and 10 references are allowed. They are
all authors should disclose any possible conflicts of but not yet accepted should be noted as [unpublished
usually invited by the Editor.
interest. Conflict of interest statements will be pub- data] and not be included in the reference list. The
lished at the end of the text of the article. Letters addressed to the Editor are encouraged if they list of references should include only those publica-
directly concern articles previously published in this tions which are cited in the text. Do not alphabet-
Ethical and Legal Prerequisites journal and clinical subjects related to the matters dis- ize; number references in the order in which they
Manuscripts involving examinations of human sub- cussed. The editor reserves the right to submit cop- are first mentioned in the text. The surnames of the
jects must include a statement that the trial protocol ies of such letters to the authors of the articles con- authors followed by initials should be given. There
has been approved by an ethical committee and thus cerned prior to publication in order to permit them should be no punctuation other than a comma to sep-
meets the standards of the Declaration of Helsinki to respond in the same issue of the journal. But letters arate the authors. Preferably, please cite all authors.
© 2015 S. Karger AG, Basel
E-Mail [email protected] The Guidelines for Authors are available at:
www.karger.com www.karger.com/ocl_Guidelines
Abbreviate journal names according to the Index rity and conclusions of the paper. Please note that Self-Archiving
Medicus system. Also see International Committee all supplementary files will undergo editorial review Karger permits authors to archive their pre-prints (i.e.
of Medical Journal Editors: Uniform requirements and should be submitted together with the original pre-refereeing) or post-prints (i.e. final draft post-ref-
for manuscripts submitted to biomedical journals manuscript. The Editors reserve the right to limit the ereeing) on their personal or institution’s servers, pro-
(www.icmje.org). scope and length of the supplementary material. Sup- vided the following conditions are met: Articles may
Examples plementary material must meet production quality not be used for commercial purposes, must be linked
(a) Papers published in periodicals: Chatel J-M, standards for Web publication without the need for to the publisher’s version, and must acknowledge the
Bernard H, Orson FM: Isolation and characterization any modification or editing. In general, supplemen- publisher’s copyright. Authors selecting Karger’s Au-
of two complete Ara h 2 isoforms cDNA. Int Arch Al- tary files should not exceed 10 Mb in size. All fig- thor’s ChoiceTM feature, however, are also permitted
lergy Immunol 2003;131:14–18. ures and tables should have titles and legends and all to archive the final, published version of their arti-
(b) Papers published only with DOI numbers: files should be supplied separately and named clearly. cle, which includes copyediting and design improve-
Theoharides TC, Boucher W, Spear K: Serum inter- Acceptable files and formats are: Word or PDF files, ments as well as citation links.
leukin-6 reflects disease severity and osteoporosis Excel spreadsheets (only if the data cannot be con-
in mastocytosis patients. Int Arch Allergy Immunol verted properly to a PDF file), and video files (.mov, Page Charges
DOI: 10.1159/000063858. .avi, .mpeg). There are no page charges for papers of 3 or fewer
(c) Monographs: Matthews DE, Farewell VT: Using printed pages (including tables, illustrations and ref-
and Understanding Medical Statistics, ed 3, revised. Author’s ChoiceTM erences). Each additional complete or partial page is
Basel, Karger, 1996.0 Karger’s Author’s ChoiceTM service broadens the charged to the author at CHF 325.00. The allotted size
(d) Edited books: Cochrane AL, Ricardo SD: Oxidant reach of your article and gives all users worldwide free of a paper is equal to approx. 7 manuscript pages (in-
stress and regulation of chemokines in the develop- and full access for reading, downloading and printing cluding tables, illustrations and references).
ment of renal interstitial fibrosis; in Razzaque MS, at www.karger.com. The option is available for a one-
Taguchi T (eds): Renal Fibrosis. Contrib Nephrol. time fee of CHF 3,000.00, which is a permissible cost Proofs
Basel, Karger, 2003, vol 139, pp 102–119. in grant allocation. More information can be found Unless indicated otherwise, proofs are sent to the cor-
Reference Management Software: Use of EndNote is at www.karger.com/authors_choice. responding author and should be returned with the
recommended for easy management and formatting least possible delay. Alterations other than the cor-
of citations and reference lists. NIH-Funded Research rection of printer’s errors are charged to the author.
The U.S. National Institutes of Health (NIH) man-
Digital Object Identifier (DOI) dates under the NIH Public Access Policy that final, Reprints
S. Karger Publishers supports DOIs as unique iden- peer-reviewed manuscripts appear in its digital da- Order forms and a price list are sent with the proofs.
tifiers for articles. A DOI number will be printed on tabase within 12 months of the official publication Orders submitted after the issue is printed are subject
the title page of each article. DOIs can be useful in date. As a service to authors, Karger submits the fi- to considerably higher prices.
the future for identifying and citing articles published nal version of your article on your behalf to PubMed
online without volume or issue information. More in- Central. For those selecting our premium Author’s
formation can be found at www.doi.org. ChoiceTM service, we will send your article immedi-
ately upon publishing, accelerating the accessibility of
Supplementary Material your work without the usual embargo. More details
Supplementary material is restricted to additional on NIH’s Public Access Policy is available at http://
data that are not necessary for the scientific integ- publicaccess.nih.gov/policy.htm
© 2015 S. Karger AG, Basel
E-Mail [email protected] The Guidelines for Authors are available at:
www.karger.com www.karger.com/ocl_Guidelines
General Information
ISSN Print Edition: 0030–2414 Subscription Rates: Subscriptions run for Back Volumes and Single Issues: Information on
ISSN Online Edition: 1423–0232 a full calendar year. Prices are given per year. availability and prices of single print issues and print
Personal subscription: or electronic back volumes can be obtained from Cus-
Journal Homepage: www.karger.com/ocl Print or Online Print+Online combined tomer Service at [email protected].
CHF 1716.00 CHF 1812.00
Publication Data: Oncology is published 12 times a EUR 1430.00 EUR 1508.00 Bibliographic Indices: This journal is regularly listed
year. Volumes 88 and 89, each with 6 issues, appear USD 1751.00 USD 1847.00 in bibliographic services, including Current Contents®
in 2015. postage and handling (added to print and print+online) and PubMed/MEDLINE.
CHF 91.20 Europe, CHF 134.40 Overseas
Copyright: © 2015 S. Karger AG, Basel (Switzerland). EUR 76.80 Photocopying: This journal has been registered with
All rights reserved. No part of this publication may be USD 124.80 the Copyright Clearance Center (CCC), as indicated by
translated into other languages, reproduced or utilized Institutional subscription: the code appearing on the first page of each article. For
in any form or by any means, electronic or mechanical, Print or Online Print+Online combined readers in the US, this code signals consent for copying
including photocopying, recording, microcopying, or CHF 3432.00 CHF 3947.00 of articles for personal or internal use, or for the per-
by any information storage and retrieval system, with- EUR 2860.00 EUR 3289.00 sonal or internal use of specific clients, provided that
out permission in writing from the publisher or, in the USD 3502.00 USD 4027.00 the stated fee is paid per copy directly to
case of photocopying, direct payment of a specified fee postage and handling (added to print and print+online) Copyright Clearance Center Inc.
to the Copyright Clearance Center. CHF 114.00 Europe, CHF 168.00 Overseas 222 Rosewood Drive
EUR 96.00 Danvers, MA 01923 (USA)
Disclaimer: The statements, opinions and data con- USD 156.00 A copy of the first page of the article must accompa-
tained in this publication are solely those of the indi- ny payment. Consent does not extend to copying for
vidual authors and contributors and not of the publish- general distribution, for promotion, for creating new
er and the editor(s). The appearance of advertisements works, or for resale. In these cases, specific written per-
in the journal is not a warranty, endorsement, or ap- mission must be obtained from the copyright owner,
proval of the products or services advertised or of their S. Karger AG, P.O. Box
effectiveness, quality or safety. The publisher and the CH–4009 Basel (Switzerland).
editor(s) disclaim responsibility for any injury to per-
sons or property resulting from any ideas, methods,
instructions or products referred to in the content or
advertisements.
Subscription Orders: or further Karger offices USA Karger China
Orders can be placed at agencies, or representatives: S. Karger Publishers, Inc. West/5F, China Life Tower
bookstores, directly with the Publisher 26 West Avon Road No.16, Chao Wai Street
Germany P.O. Box 529 Chaoyang District
S. Karger AG S. Karger GmbH Unionville, CT 06085 Beijing 100020
Medical and Scientific Publishers Postfach USA China
Allschwilerstrasse 10 79095 Freiburg Toll free: [phone] t: [phone]
CH–4009 Basel Deutschland t: [phone] f: [phone]
Switzerland (Hausadresse: Wilhelmstrasse 20A, f: [phone] e: [email protected]; [email protected]
79098 Freiburg) e: [email protected] w: www.karger.cn
t: [phone] t: [phone]
f: [phone] f: [phone] France India, Bangladesh, Sri Lanka
e: [email protected] e: [email protected] Enter & Read Karger India
w: www.karger.com w: www.karger.de Albertine Luginbuhl Plot No. 17, Yusuf Sarai Market
23, rue du Départ, boite 37 B.L. Glass Building, 2nd Floor
(for courier services only: Japan 75014 Paris Sri Aurobindo Marg
Allschwilerstrasse 10 Karger Japan, Inc. France New Delhi 110 016
CH–4055 Basel) Shiba Daimon Asahi Bldg. 2F t: [phone] India
1-2-23 Shiba Daimon e: [email protected] t: [phone]
Minato-ku f: [phone]
Tokyo 105-0012 South East Asia, China and Taiwan c: [phone]
Japan Karger Regional Office (Malaysia) e: [email protected]
t: [phone] Level 28-03-03A, PJ Exchange w: www.karger.com
f: [phone] No. 16A, Persiaran Barat
e: [email protected] 46050 Petaling Jaya
w: www.karger.jp Selangor Darul Ehsan
Malaysia
t: [phone]
f: [phone]
e: [email protected]; [email protected]
Change of Address:
Both old and new address should be sent
to the subscription source.
© 2015 S. Karger AG, Basel
E-Mail [email protected] The Guidelines for Authors are available at:
www.karger.com www.karger.com/ocl_Guidelines
Contents
See the journal website for contents
Basel • Freiburg • Paris • London • New York • New Delhi • Bangkok •
Beijing • Tokyo • Kuala Lumpur • Singapore • Sydney
Organized in association with:
International Extranodal Lymphoma Study Group
and “Foundation for the Research and Cure of Lymphoma in Ticino”
13-ICML
13th International Conference on Malignant Lymphoma
VENUE AND DATE: Palazzo dei Congressi, Lugano (Switzerland)
June 17-20, 2015
IMPORTANT February 28, 2015 - ABSTRACT SUBMISSION
DEADLINES: March 13, 2015 - EARLY REGISTRATION
May 22, 2015 - GROUP REGISTRATION
FOR ANY INFORMATION, Cristiana Brentan
PLEASE CONTACT: ICML Secretariat
IOSI, Ospedale San Giovanni, CH-6500 Bellinzona
e-mail: [email protected]
www.lymphcon.ch
13-ICML is supported by ESO – European School of Oncology.
ICML program will be part of the Certificate of Competence in Lymphoma, a 1-year ECTS program
developed by ESO and academically recognized by Ulm University.
Furthermore, cooperation is established within the Leukaemia and Lymphoma course
(13-16 June 2015, Ascona, Switzerland). 6
2
1
For further information, please visit www.eso.net 15
F
Onco Update Europe 2015
1st European Update Congress in Oncology
Vienna, 19 – 20 June 2015
Cancer Biology and
Targeted Treatment
Complete medical fi eld in two days Giampaolo Tortora (Italy)
Cutting-edge study results Lymphoma and Myeloma
Heinz Ludwig (Austria)
Ensured practical relevance
Acute and Chronic
Submit Myeloid Leukemia
an ePoster Gert Ossenkoppele (Netherlands)
Save
200 € Melanoma
Axel Hauschild (Germany)
Gynecological Cancer
Andrés Cervantes (Spain)
Radiation Oncology
Marcel Verheij (Netherlands)
Genito-urinary Tract Cancer
Silke Gillessen (Switzerland)
Lung Cancer
Jan van Meerbeeck (Belgium)
Tumors of the
Central Nervous System
Marc Sanson (France)
Sarcoma and GIST
Ian Judson (UK)
Upper Gastrointestinal
Tract Cancer
Florian Lordick (Germany)
Scientifi c board
Florian Lordick (Germany)
Colorectal Cancer
Andrés Cervantes (Spain) Alberto Sobrero (Italy)
Heinz Ludwig (Austria)
Marcel Verheij (Netherlands) Head & Neck Cancer
Andreas Dietz (Germany)
Registration and further information
Breast Cancer
Michael Gnant (Austria)
www.onco-update-europe.eu
F15115
Partner Educational Grant Congress host
Extraordinary insights into an ordinary pathology
Actinic Keratosis
Current Problems in Dermatology
Editors: P. Itin, G.B.E. Jemec
Vol. 46
Actinic
Keratosis Editors
H. Peter Soyer
Editors Tarl W. Prow
H.P. Soyer
TG..WB.. EP.r Joewmec Gregor B.E. Jemec
Actinic Keratosis In some respects actinic keratosis is the most com- • The Many Clinico-Pathologic Faces of Actinic Keratosis:
Editors: Soyer, H.P.; Prow, T.W. (Brisbane, Qld.); mon and best-known pathology in dermatology. An Atlas: Massone, C.; Cerroni, L.
JVeIImI +e c1,5 G4. Bp..E, .3 (3R ofisgk.,i l2d9e )in color, 4 tab., 2015 Being such an ordinary pathology, actinic keratosis • DCaerrcminoosmcoap ayn odf SAqcutianmico Kuesr aCteolsl iCs,a Irnctirnaoempiad:e Zramlaaul dek, I.;
CHF 189.00 / EUR 158.00 / USD 222.00 (hard cover) gives nevertheless insight into an extraordinary num-
Argenziano, G.
CHF 227.00 / EUR 190.00 / USD 266.00 (online) ber of important biological and clinical processes. • The Future of Keratinocyte Skin Cancer Surveillance:
Online version for institutional purchase,
prices subject to change Actinic keratoses are found in significant numbers on Automated Image Analysis to Identify and Monitor
EUR price for Germany, USD for USA the sun-exposed skin of Caucasians, especially those Keratinocyte Dysplasia: Hames, S.C.; Prow, T.W.
and Latin America living in sun-bathed countries such as Australia, as • Reflectance Confocal Microscopy: Hallmarks of
ISBN 978–3–318–02762–4 (hard cover) Keratinocyte Cancer and Its Precursors: Prow, T.W.;
e-ISBN 978–3–318–02763–1 two of the editors and a considerable number of the Tan, J.-M.; Pellacani, G.
authors of this book do. • Optical Coherence Tomography and Its Role for
Current Problems in Dermatology, Vol. 46 The authors who have contributed to this volume are Delineating the Thickness of Keratinocyte Dysplasia and
Series Editor: Itin, P. (Basel); Jemec, G.B.E.
(Roskilde) researchers and clinicians discussing actinic keratosis Neoplasia: Themstrup, L.; Jemec, G.B.E.
across the whole spectrum – from epidemiology to • Teledermatology: Its Use in the Detection and
immunology, from molecular biology to behavioral Management of Actinic Keratosis: Janda, M.
• Conventional Treatment of Actinic Keratosis: An Overview:
psychology – and of course pathologists and clini-
Peris, K.; Fargnoli, M.C.
cians dealing with patients who experience the • Field Cancerization: From Molecular Basis to Selective
many manifestations of actinic keratoses. The fact Field-Directed Management of Actinic Keratosis:
that all these various aspects are considered renders Philipp-Dormston, W.G.
this book valuable reading for scientists and clinicians • Update on Photodynamic Treatment for Actinic Keratosis:
Wiegell, S.R.
alike.
• Laser Treatment and Its Implications for Photodamaged
Skin and Actinic Keratosis: de Vries, K.; Prens, E.P.
• Ingenol Mebutate: From Common Weed to Cancer Cure:
Contents Zarchi, K.; Jemec, G.B.E.
• Oral Nicotinamide and Actinic Keratosis: A Supplement
Preface: Soyer, H.P.; Prow, T.W.; Jemec, G.B.E. Success Story: Kim, B.; Halliday, G.M.; Damian, D.L.
• Epidemiology of Actinic Keratoses: Green, A.C.
• Patients’ Perspectives on Actinic Keratoses: Esmann, S. Author Index/Subject Index
• Photodamage: All Signs Lead to Actinic Keratosis and Early
Squamous Cell Cancer: Wei, J.; Kok, L.F.; Byrne, S.N.;
Halliday, G.M.
• Dysregulation of Epidermal Growth Factor Receptor in
Dear Librarian Actinic Keratosis and Squamous Cell Carcinoma:
I have reviewed this publication and Joseph, S.R.; Endo-Munoz, L.; Gaffney, D.C.; Saunders, N.A.;
would like to recommend it for our library. Simpson, F.
• The Actinic Keratosis Virome: Can We Prevent Squamous
Recommended by:
Cell Carcinoma with a Vaccine? Frazer, I.H.
• Do Actinic Keratoses and Superficial Squamous Cell
Carcinomas Have a Specific Immunoprofile? Wells, J.W.
• Mouse Models for Actinic Keratosis and Squamous Cell
Department: Carcinoma: Handoko, H.Y.; Ferguson, B.; Walker, G.J.
• Keratinocyte Cancer and Its Precursors in Organ Transplant
Patients: Jenni, D.; Hofbauer, G.F.L.
• Clinical Features of Actinic Keratoses and Early Squamous
Cell Carcinoma: Wheller, L.; Soyer, H.P.
Date:
The easiest way to order: www.karger.com/cupde
Signature:
0
0
Karger – Medical and Scientific Publishers 52
1
Orders may be placed with any bookshop, CH–4009 Basel, Switzerland KI
[email protected], f: [phone]
subscription agency, directly with the publisher
www.karger.com
or through a Karger distributor.